3/29/23, 12:00 PM 496

Official reprint from UpToDate®

www.uptodate.com © 2023 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Generalized anxiety disorder in adults: Epidemiology,

pathogenesis, clinical manifestations, course,
assessment, and diagnosis
Author: David Baldwin, MA, DM FRCPsych
Section Editor: Murray B Stein, MD, MPH
Deputy Editor: Michael Friedman, MD

All topics are updated as new evidence becomes available and our peer review process is complete.

Literature review current through: Feb 2023. | This topic last updated: Apr 18, 2022.

INTRODUCTION

Generalized anxiety disorder (GAD) is characterized by excessive and persistent worry that is
difficult to control, causes significant distress or impairment, and occurs on more days than not
for at least six months. Other features include psychological symptoms such as apprehension
and irritability, and physical (or somatic) symptoms such as increased fatigue and muscular
tension.

This topic addresses the epidemiology, pathogenesis, clinical manifestations, and diagnosis of
GAD. Pharmacotherapy for GAD, psychotherapy for GAD, and issues concerning treatment and
assessment of comorbid disorders are discussed separately:

● (See "Generalized anxiety disorder in adults: Management".)

● (See "Generalized anxiety disorder in adults: Cognitive-behavioral therapy and other
psychotherapies".)
● (See "Co-occurring substance use disorder and anxiety-related disorders in adults:
Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis".)
● (See "Comorbid anxiety and depression in adults: Epidemiology, clinical manifestations,
and diagnosis".)

https://www.uptodate.com/contents/496/print 1/20
3/29/23, 12:00 PM 496

EPIDEMIOLOGY

Prevalence — Generalized anxiety disorder (GAD) is one of the most common mental disorders
in both community and clinical settings. It is associated with increased use of health care
services [1,2].

Epidemiologic studies of nationally representative samples in the United States report a past-
year prevalence of GAD to be 2.7 to 3.1 percent [3,4] and a lifetime prevalence of GAD of 5.1
[2,5] to 11.9 percent [6]. A review of epidemiological studies in Europe found a past-year
prevalence of 1.7 to 3.4 percent [7], and a lifetime prevalence of 4.3 to 5.9 percent [8].
Worldwide, estimates of the lifetime and 12-month prevalence are 3.7 and 1.8 percent,
respectively [9].

The disorder is approximately twice as common in females as it is in males [2,6].

Comorbidity — Comorbidity with major depression or other anxiety disorders is commonly

observed in GAD.

In a nationally representative survey of United States adults, 66 percent of individuals with

current GAD had at least one concurrent psychiatric disorder while 90 percent of individuals
with lifetime GAD had at least one comorbid psychiatric disorder [2]. Lifetime comorbidity,
worldwide, has been estimated as 81.9 percent [9].

Comorbid disorders can affect the clinical course of GAD [10-12].

Major depressive disorder appears to be the most common comorbidity in individuals with
current or lifetime GAD. Comorbid major depression is reported in 39 percent of individuals
with current GAD and 62 percent of individuals with lifetime GAD [2,7]. Worldwide, mood
disorders have an estimated lifetime comorbidity of 63 percent [9].

Other disorders found to co-occur in individuals with GAD (rates over previous 30 days and
lifetime) include [2,13]:

● Social phobia – 23 and 34 percent

● Specific phobia – 25 and 35 percent
● Panic disorder – 23 and 24 percent

GAD may also be associated with increased rates of alcohol and other substance use disorders,
posttraumatic stress disorder, and obsessive-compulsive disorder.

https://www.uptodate.com/contents/496/print 2/20
3/29/23, 12:00 PM 496

GAD is common among patients with “medically unexplained” chronic pain [14] and with
chronic physical illness [15].

● (See "Unipolar depression in adults: Epidemiology".)

● (See "Social anxiety disorder in adults: Epidemiology, clinical manifestations, and
diagnosis".)
● (See "Specific phobia in adults: Epidemiology, clinical manifestations, course and
diagnosis".)
● (See "Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis".)

PATHOGENESIS

Biological factors

● Genetics – Genetic factors appear to predispose individuals to the development of

generalized anxiety disorder (GAD) [16]. GAD shares a common heritability with major
depression [17] and with the personality trait of “neuroticism” [18,19]. Other data support
variations in subtypes of glutamic acid decarboxylase gene as increasing susceptibility to
GAD [20,21], and increased frequency of the serotonin transporter gene-linked
polymorphic region SS genotype in individuals with GAD [22].

Furthermore, gene-environment studies have highlighted the importance of early

developmental trauma and recent stressful life events and their interaction with genetic
markers in the development of GAD and anxiety sensitivity [16].

● Neurotransmitter disturbances and other biomarkers – Investigations of disturbances

in neurotransmitters and other biomarkers in GAD tend to have been small or
unreplicated [23-29].

Evidence of possible neurotransmitter disturbances in individuals with GAD is supported

by the following:

• Two observational studies including a total of 60 individuals reported elevated levels of

norepinephrine metabolites 3-methoxy-4-hydroxyphenylgycol and vanillylmandelic in
individuals with GAD versus those without GAD [23,24].

• An observational study reported blunted growth hormone response to clonidine in 11

individuals with GAD compared with 14 healthy subjects [25]. This suggests decreased
postsynaptic alpha-2 adrenergic receptor sensitivity in individuals with GAD.

https://www.uptodate.com/contents/496/print 3/20
3/29/23, 12:00 PM 496

• In an observational study including 46 individuals with GAD, elevated urinary levels of

the serotonin metabolite 5-hydroxyindoleacetic acid appeared to be associated with
greater somatic anxiety symptoms, but not psychic anxiety symptoms [24].

Other data suggests the role of acid-sensing ion channels in the amygdala [28] and
elevated levels of C reactive protein and other proinflammatory cytokines [29] as
potentially involved in the development of GAD.

● Neuroimaging and brain metabolism – In individuals with GAD, localized morphologic

changes in white matter volume have been reported [30]. In one cohort study, magnetic
resonance imaging (MRI) of 22 individuals with GAD were compared with MRI of 22
healthy controls. The diagnosis of GAD was associated with reduced white matter volume
in the dorsolateral prefrontal cortex, anterior limb of the internal capsule, and midbrain.

Additionally, alterations in glucose metabolism in the cortex, limbic system, and basal
ganglia suggest their role in the development of anxiety. For example, in one study,
positron emission tomography (PET) of 18 individuals with GAD were compared with PET
of 15 individuals without GAD (control group) [31]. PET scans of individuals with GAD
demonstrated a relative increase in glucose metabolism in parts of the occipital, right
posterior temporal lobe, inferior gyrus, cerebellum and right frontal gyrus, and an
absolute decrease in the basal ganglia versus control group.

In a separate functional MRI study, individuals with GAD showed greater anticipatory
activity in the bilateral dorsal amygdala to both aversive and neutral pictures [32]. This
suggests an enhanced anticipatory emotional responsiveness in GAD [31,32]. A systematic
review of neuroimaging studies found that GAD patients show difficulties in engaging the
prefrontal cortex and anterior cingulate cortex during emotional regulation tasks [33].

Cognitive, psychological, and developmental factors

● Processing of emotional information – Individuals with GAD show a consistent bias

towards generating negative interpretations of ambiguous material [34,35]. Additionally,
they tend be vigilant to threatening stimuli, often detecting “threats” rapidly [36],
particularly when the threat is presented in verbal-linguistic format (ie, words) rather than
pictorial form [37].

These biases appear to diminish with successful treatment with cognitive-behavioral

therapy [38] or a selective serotonin reuptake inhibitor [39].

https://www.uptodate.com/contents/496/print 4/20
3/29/23, 12:00 PM 496

● Developmental and personality factors – GAD in adults is associated with a higher than
average number of traumatic experiences and other undesirable life events in childhood,
compared with individuals without GAD [40]. Childhood maltreatment confers an
increased risk of developing GAD following stressful experiences [41].

GAD is more likely to occur in individuals with “behavioral inhibition” (the tendency to be
timid and shy in novel situations), than without this trait. Additionally, neuroticism (an
enduring tendency to worry and feel anxious, sad, or guilty) is associated with comorbid
GAD and major depression [42-44]. (See "Social anxiety disorder in adults: Epidemiology,
clinical manifestations, and diagnosis", section on 'Behavioral inhibition'.)

● Cognitive origins of worry – Many explanations of the origin and persistence of the
excessive and pervasive worrying that characterize GAD have been proposed. As
examples, affected individuals may:

• Constantly scan the environment for cues of threat [45]

• Develop worrying in an attempt to solve problems [46]
• Use worrying to avoid the fear response [47]
• Have intolerance of uncertainty or ambiguity [48]
• Worry about the uncontrollability and presumed dangerous consequences of worrying
[49]

CLINICAL FEATURES AND COURSE

Characteristic symptoms — Individuals with generalized anxiety disorder (GAD) experience

excessive worry or anxiety about health, work, interpersonal relationships, or other life events.
Generally, these worries seem realistic; however, they are typically out of proportion to the
impact of the anticipated event or the object of worry. The symptoms cause distress or
impairment in psychosocial functioning. Furthermore, individuals with GAD report greater
worries over minor matters (eg, household chores, car repairs, being late for an appointment)
than controls [49].

Other presenting symptoms may include restlessness or hyperarousal, fatigue, irritability, poor
concentration, sleep disturbance, and muscle tension. These are often chronic and unexplained
despite repeated presentation to health care professionals.

Onset — The average age of onset of GAD is 30 years, although the range is broad [50]. While
subsyndromal anxiety symptoms are common before the age of 20, full syndromal disorder

https://www.uptodate.com/contents/496/print 5/20
3/29/23, 12:00 PM 496

typically occurs later than other anxiety disorders (eg, separation anxiety disorder, phobias,
panic disorder) [51,52].

Studies examining the effect of age of onset on the course of GAD have shown mixed results.
While some studies have suggested that earlier age of onset is associated with a more
protracted course [53], others find that early-onset GAD does not constitute a more severe
subtype [54].

● Late-onset generalized anxiety – Late-onset GAD (onset ≥50 years) is thought to

represent the most common anxiety disorder among older adult populations [7,55].
Individuals with late-onset GAD are more likely to a report a poorer health-related quality
of life than individuals with earlier onset GAD [55-57].

In a community survey including 1974 adults age ≥65 years, nearly 25 percent reported a
late onset of generalized anxiety symptoms [58]. Factors associated with late-onset GAD
include female sex, chronic physical illness (eg, respiratory, cardiovascular, cognitive),
current major depression or phobia, recent adverse life events, negative childhood events
(eg, parental loss or separation, parental mental health problems), financial difficulties,
and past history of GAD [56,59].

Chronicity of symptoms — GAD is a chronic illness with fluctuating symptom severity. In

approximately half of the cases, there are intervening symptom free periods [52].

In one prospective study of 179 individuals with GAD, approximately 60 percent of patients
recovered over 12 years (ie, had no more than residual symptoms for eight consecutive weeks),
but approximately one-half of recovered patients subsequently relapsed during the 12-year
period [60].

In another prospective study involving 142 subjects with GAD followed for 14 years, the severity
of anxiety symptoms over time decreased only modestly [61].

However, studies of individuals in community samples suggest a better prognosis than studies
of clinical populations. In one 22-year follow-up study of 105 community living individuals with
GAD found that less than 20 percent had persistent GAD (defined by the presence of daily
symptoms over the previous 12 months) [52].

Effects of illness

Psychosocial effects — GAD is associated with substantial psychosocial impairment across

several life domains including occupational, social, and household functioning [62]. In some

https://www.uptodate.com/contents/496/print 6/20
3/29/23, 12:00 PM 496

cases, the level of impairment is greater than is seen in individuals with major depression
[63,64].

For example, in a national epidemiologic survey of adult mental health in Germany (n = 4181),
the impact of psychiatric symptoms on daily functioning and perceived quality of life was
assessed [64]. A greater percentage of respondents with the diagnosis of GAD reported six or
more days with impairment (defined as inability to work or carry out everyday activities) over
the past month than respondents with major depression or no diagnosis (34 versus 21 versus 2
percent respectively). Furthermore, lower scores on measures of quality of life including general
health and mental health (as measured on the 100-point Medical Outcomes Study Short Form-
36) were seen in individuals with GAD versus major depression versus no diagnosis (general
health: 47 versus 59 versus 68 respectively; mental health: 34 versus 42 versus 51, respectively).

The presence of comorbid disorders such as major depression appear to be associated with
more severe and prolonged course of illness and greater functional impairment [6,12,60]. For
example, in a national survey, a greater percentage of individuals with both GAD and major
depression reported six or more days of impairment in the past month than individuals with
either GAD or major depression (48 versus 34 versus 21 percent respectively) [64]. Additionally,
the survey showed that a greater percentage of individuals with both disorders had over 50
percent reduction in overall activities than individuals with generalized anxiety or major
depression (23 versus 11 versus 8 percent respectively). (See 'Comorbidity' above.)

Systemic effects — GAD is associated with poor cardiovascular health, coronary heart disease
[65], and cardiovascular mortality [66]. Relationships between worry and cardiovascular
changes include observations that excessive worrying leads to diminished heart rate variability,
elevated heart rate, hypertension, and increased antihypertensive use [65]. Additionally, greater
severity of worry has been associated with higher rates of fatal and nonfatal coronary heart
disease. Evidence to support the contention that worry may be beneficial to cardiovascular
function or health promoting behaviors has not been found [65].

Prospective studies suggest that clinically significant anxiety in the midlife period may be an
independent risk factor for the development of dementia [67].

ASSESSMENT AND DIAGNOSIS

Assessment

History — Our primary goal in assessing individuals with anxiety is differentiating anxiety due
to generalized anxiety disorder (GAD) from anxiety that may be due to other causes and
https://www.uptodate.com/contents/496/print 7/20
3/29/23, 12:00 PM 496

determining if the anxiety warrants treatment or not. We use history as the primary tool to
accomplish these goals.

● First, we assess the frequency, character, and severity of symptoms to raise or lower
suspicion for the diagnosis of GAD by asking the following questions. Using a symptom
scale, such as the GAD seven-item (GAD-7) scale (calculator 1), can also be helpful to try to
quantify the severity of symptoms (see 'Quantifying the severity of symptoms' below):

• Does the anxiety concern every day or routine circumstances or events (eg, job
responsibility, health of self or family members, finances, misfortunes, or other minor
tasks such as household chores)?

• Is the anxiety difficult to control?

• Are associated symptoms such as restlessness, concentration problems, irritability,

tension, or fatigue present?

• Have the symptoms been present for more than six months?

• Are the symptoms present more days than not?

• Do the symptoms cause significant distress to the individual or is there impairment in

social, occupational, or other areas of functioning as a result of the anxiety?

In individuals who answer yes to all of the above questions we further consider the
diagnosis of GAD and rule out other diagnoses that present with similar or overlapping
syndromes and other comorbid diseases. (See 'Diagnostic criteria' below and 'Differential
diagnosis' below.)

Individuals who answer no to any of these questions probably do not meet the American
Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition (DSM-5) criteria for GAD.

● For people who would meet DSM-5 criteria for GAD or have a likely diagnosis of GAD
based on the severity and frequency of symptoms as above, we review prior psychiatric
history and rule out other psychiatric diagnoses as potential causes of anxiety. We do this
by establishing the presence or absence of symptoms that may differentiate between
disorders:

• Mood symptoms – Dysphoria or elevated mood, sleep disturbance, early morning

awakening, irritability, fatigue, guilt, suicidal ideation could suggest depression or

https://www.uptodate.com/contents/496/print 8/20
3/29/23, 12:00 PM 496

mania if they are more prominent than the anxiety.

• Specific worries about potential medical illness or somatic symptoms – These suggest a
focused anxiety disorder (eg, illness-anxiety disorder) rather than a GAD.

• Rapid onset and resolution of symptoms – Symptoms that start rapidly, sharply rise in
intensity, peak within an hour, and then decline are suggestive of discrete anxiety
attacks which suggests panic disorder rather than GAD.

• Presence of recurrent or intrusive thoughts – The presence of these with associated

repetitive behaviors that are performed to neutralize the intrusive thoughts suggest a
diagnosis of obsessive-compulsive disorder (OCD) rather than GAD.

• Recent psychosocial stressor – The presence of recent stressors such as relationship

problems, career problems, or loss of a loved one suggest a diagnosis of an
adjustment disorder or acute stress disorder as the underlying cause of the anxiety.

These and other psychiatric disorders that can share symptomatology with GAD are
discussed in further detail elsewhere. It is also possible for these disorders to coexist with
GAD. (See 'Differential diagnosis' below.)

● We ask about physical health problems (eg, thyroid disease, asthma) and their effects. We
review the individual’s use of prescribed medications (eg, steroids, bronchodilators) as
these may be causing or worsening the anxiety. We also ask about alcohol and other
substance use or recent abstinence from alcohol or other substances.

Physical examination and laboratory testing in select individuals — For individuals with
suspected physical cause of anxiety (eg, individuals with weight loss, cognitive impairment,
shortness of breath) and in individuals with later onset of generalized anxiety (eg, older than 50
years) we do a general physical screening examination and laboratory testing to screen for
underlying medical disorders. We typically obtain a complete blood count, chemistry panel,
serum thyrotropin, urinalysis, electrocardiogram (in patients over 40 with chest pain or
palpitations), and urine toxicology. In cases with suspected underlying medical cause, we refer
to the appropriate specialist for further evaluation.

In older individuals the co-occurrence of long-term physical illness, chronic insomnia,

cognitive impairment, and side effects of prescribed medication can make the diagnosis
more difficult. Older adult individuals with GAD may assert that anxiety or fear is a realistic
response to their social environment, recent life events, and current challenges.

https://www.uptodate.com/contents/496/print 9/20
3/29/23, 12:00 PM 496

Quantifying the severity of symptoms — In all individuals with symptoms suspicious for
GAD, we use the GAD-7 scale (calculator 1) as a means of measuring the level of anxiety.
Additionally, in individuals with confirmed GAD we use the GAD-7 periodically, to monitor
symptoms and judge the response to treatment. The GAD-7 has acceptable reliability and
validity [68] and is sensitive to change in symptoms [69].

The Penn State Worry Questionnaire is available in a number of languages but does not assess
all key symptoms and may be less sensitive to change than the GAD-7 [69].

For hospitalized individuals with active medical disorders, we use the Hospital Anxiety and
Depression Scale to assess and monitor the severity of anxiety and depression. It is useful in
identifying pathological anxiety, has separate subscales for anxiety and depression, and
includes questions that can distinguish symptoms of GAD from anxiety associated with other
medical conditions [68].

Diagnostic criteria — We diagnose GAD in individuals with excessive anxiety and worry that
occur on more days than not for at least six months, are associated with somatic symptoms
(muscle tension, irritability, sleep disturbance), are not due to effects of substances or another
medical condition, and cause clinically significant distress or impairment in social, occupation,
or other important areas of functioning. In patients who “fall short” of the severity or duration
thresholds, further review is advisable, particularly in those who are significantly distressed or
impaired in functioning.

Specifically, the DSM-5 diagnostic criteria for GAD are [50]:

● A. Excessive anxiety and worry (apprehensive expectation), occurring more days than not
for at least six months, about a number of events or activities (such as work or school
performance).

● B. The individual finds it difficult to control the worry.

● C. The anxiety and worry are associated with three (or more) of the following six
symptoms (with at least some symptoms having been present for more days than not for
the past six months):

Note: Only one item is required in children.

• 1. Restlessness or feeling keyed up or on edge

• 2. Being easily fatigued

https://www.uptodate.com/contents/496/print 10/20
3/29/23, 12:00 PM 496

• 3. Difficulty concentrating or mind going blank

• 4. Irritability

• 5. Muscle tension

• 6. Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep)

● D. The anxiety, worry, or physical symptoms cause clinically significant distress or

impairment in social, occupational, or other important areas of functioning.

● E. The disturbance is not attributable to the physiological effects of a substance (eg, a

drug of abuse, a medication) or another medical condition (eg, hyperthyroidism).

● F. The disturbance is not better explained by another mental disorder (eg, anxiety or worry
about having panic attacks in panic disorder, negative evaluation in social anxiety disorder
[social phobia], contamination or other obsessions in OCD, separation from attachment
figures in separation anxiety disorder, reminders of traumatic events in posttraumatic
stress disorder, gaining weight in anorexia nervosa, physical complaints in somatic
symptom disorder, perceived appearance flaws in body dysmorphic disorder, having a
serious illness in illness anxiety disorder, or the content of delusional beliefs in
schizophrenia or delusional disorder). Because the majority of the anxiety symptoms are
not specific to GAD, it is important to exclude the other anxiety disorders before making
the diagnosis.

• (See "Social anxiety disorder in adults: Epidemiology, clinical manifestations, and

diagnosis".)
• (See "Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis".)
• (See "Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical
manifestations, course, assessment, and diagnosis".)
• (See "Obsessive-compulsive disorder in adults: Epidemiology, pathogenesis, clinical
manifestations, course, and diagnosis".)
• (See "Specific phobia in adults: Epidemiology, clinical manifestations, course and
diagnosis".)

The essential feature of diagnostic criteria for GAD in the World Health Organization
International Classification of Diseases, 11th revision (ICD-11) is generalized apprehension or
excessive worry, together with additional symptoms such as muscular tension, subjective
experience of nervousness, difficulty maintaining concentration, irritability, or sleep
disturbance. Symptoms have to be present for most days over the preceding several months.

https://www.uptodate.com/contents/496/print 11/20
3/29/23, 12:00 PM 496

The diagnosis of GAD in children and adolescents is discussed further separately. (See "Anxiety
disorders in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and
course".)

Differential diagnosis — Anxiety is a symptom that is seen in many disorders and

nonpathological states (eg, stress-related anxiety). To diagnosis GAD, we rule out other
disorders that may present with similar symptoms. These include: (See 'Assessment and
Diagnosis' above.)

● Depression – GAD, major depression, and persistent depressive disorder (“dysthymia”),

may share some presenting features such as an insidious onset, protracted course,
prominent dysphoria, and anxiety. We differentiate individuals with primary GAD from
those with other depressive disorders by the characteristics of the worry and the presence
or absence of associated symptoms. For example, individuals with depression tend to
brood self-critically about previous events and circumstances, whereas patients with GAD
tend to worry about future events. Furthermore, symptoms such as early morning
awakening, diurnal variation in mood, marked guilty preoccupations, and suicidal
thoughts may be present in depression but are uncommon in GAD. (See "Unipolar
depression in adults: Assessment and diagnosis".)

● Illness anxiety disorder and somatic symptom disorder – We differentiate symptoms of

GAD from illness anxiety disorder and somatic symptom disorder by the content of the
worries. For example, while worry about unexplained symptoms may be common in all
three of these disorders, worry in GAD usually concerns multiple different aspects of life
(physical symptoms, work, interpersonal, academics). This contrasts with individuals with
illness anxiety disorder who principally worry about developing an illness but have few or
mild physical symptoms. This also contrasts with individuals with somatic symptom
disorder who have concerns about specific and, often multiple, somatic symptoms. (See
"Illness anxiety disorder: Epidemiology, clinical presentation, assessment, and diagnosis"
and "Somatic symptom disorder: Epidemiology and clinical presentation".)

● Panic disorder – We use the presence of unexpected or paroxysmal panic attacks in

differentiating panic disorder from severe uncontrollable worry associated with GAD.
Individuals with panic disorder have paroxysmal panic attacks whereas these are not
typical in individuals with GAD. While individuals with either disorder may focus on
physical or somatic symptoms, individuals with panic disorder typically have episodic and
intense periods of extreme worry about life-threatening acute illnesses, whereas patients
with GAD focus more persistently on less specific but more chronic complaints typically

https://www.uptodate.com/contents/496/print 12/20
3/29/23, 12:00 PM 496

involving multiple organ systems. (See "Panic disorder in adults: Epidemiology, clinical
manifestations, and diagnosis".)

● Adjustment disorder – We differentiate anxiety associated with adjustment disorder from

GAD by the presence of an identifiable stressor or stressors occurring within three months
of the symptoms in adjustment disorder. In GAD, the symptoms are chronic and while they
may be related to chronic stressors of life, when they are within three months of an acute
stressor, the diagnosis of adjustment disorder is made.

● Obsessive-compulsive disorder – Individuals with GAD may manifest intrusive thoughts

and checking behaviors similar to those seen in OCD. However, in GAD the themes are
more often related to day to day worries (eg, finances, health, family), while in OCD the
compulsive behaviors tend to be related to primal fears such as contamination or harm.
Furthermore, in OCD the compulsions tend to be ritualistic or “rule driven” (eg, must be
done in a certain way) and either unrelated to the feared outcome (eg, avoiding cracks on
the sidewalk to prevent mother’s death) or clearly excessive. This contrasts to GAD in
which the checking is usually related to a feared outcome (eg, checking locks to prevent
break-ins), and is usually not as time consuming or impairing. (See "Obsessive-compulsive
disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, and
diagnosis".)

● Nonpathological anxiety – A spectrum of nonpathological anxiety is seen in many

individuals. We differentiate nonpathological anxiety from generalized anxiety by the
effect of the worry or anxiety on the individual. In GAD, the symptoms cause significant
distress or impairment in social, occupational or other areas of functioning. This contrasts
with nonpathological anxiety where there is minimal or no effect on these areas of
functioning. Subjectivity among individuals can make this differentiation difficult. To
accurately differentiate GAD from nonpathological anxiety, we pay careful attention to the
details of the history including work and psychosocial history for evidence of distress or
impairment secondary to the anxiety. As an example, in an individual with anxiety that
does not cause a change in the functioning at work (no missed deadlines, difficulty
completing tasks, lateness, or concentration problems) and no other psychosocial
changes, we would not be likely to diagnose GAD. In appropriate cases, we obtain
collateral information from family members.

SOCIETY GUIDELINE LINKS

https://www.uptodate.com/contents/496/print 13/20
3/29/23, 12:00 PM 496

Links to society and government-sponsored guidelines from selected countries and regions
around the world are provided separately. (See "Society guideline links: Anxiety and anxiety
disorders in adults".)

SUMMARY AND RECOMMENDATIONS

● Epidemiology – Generalized anxiety disorder (GAD) is one of the most common

psychiatric disorders in community and clinical settings and is associated with increased
use of health care services. It is nearly twice as common in females as males. Common
comorbidities include depression, panic disorder, and phobia. (See 'Epidemiology' above.)

● Clinical manifestations – Individuals with GAD experience worry about typical life
experiences such as work, health, and interpersonal relations. The symptoms are out of
proportion to the impact of the anticipated event. Other presenting symptoms commonly
include hyperarousal, autonomic hyperactivity, irritability, poor sleep, and unexplained
pain or muscle tension.

● Course – GAD usually has a gradual onset with subsyndromal anxiety commonly
presenting before age 20. The average onset of the disorder is 30. Late-onset GAD (eg, ≥50
years) is common and is associated with poor health-related quality of life. (See 'Onset'
above.)

GAD tends to be a persistent illness with fluctuating symptom severity. It is associated

with substantial psychosocial impairment including occupational, social, and household
functioning. The presence of comorbid disorders (eg, depression) is associated with more
severe and prolonged course and greater impairment. (See 'Chronicity of symptoms'
above and 'Effects of illness' above.)

GAD is associated with poor cardiovascular health, coronary heart disease, and
cardiovascular mortality. (See 'Systemic effects' above.)

● Assessment – For patients who present with anxiety, we assess whether the frequency,
character, and severity of symptoms are consistent with GAD. We also evaluate for other
alternative or comorbid psychiatric and medical conditions that may also contribute to
anxiety. In individuals with a suspected physical cause of anxiety (eg, weight loss,
confusion) and in individuals with later onset (>50 years old) of generalized anxiety, we do
a general physical screening examination and laboratory screening. (See 'Assessment'
above.)

https://www.uptodate.com/contents/496/print 14/20
3/29/23, 12:00 PM 496

● Diagnosis – We diagnose GAD in individuals with excessive anxiety and troublesome

worry that occur on more days than not for at least six months, are associated with
somatic symptoms (muscle tension, irritability, sleep disturbance), are not due to effects of
substances or another medical condition, and cause clinically significant distress or
impairment in social, occupation, or other important areas of functioning. (See 'Diagnostic
criteria' above.)

● Differential diagnosis – We differentiate anxiety due to GAD from other disorders that
may present with overlapping symptoms (eg, depression, panic disorder, adjustment
disorder) primarily by history. Major depression is particularly difficult to distinguish from
GAD due to shared symptoms of insidious onset, protracted course, and the presence of
dysphoria and anxiety. (See 'Differential diagnosis' above.)

Use of UpToDate is subject to the Terms of Use.

REFERENCES

1. Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary
care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63 Suppl 8:24.
2. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the
National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:355.

3. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month
DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry
2005; 62:617.

4. Kessler RC, Wang PS. The descriptive epidemiology of commonly occurring mental
disorders in the United States. Annu Rev Public Health 2008; 29:115.
5. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions
of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry
2005; 62:593.
6. Kessler RC, Gruber M, Hettema JM, et al. Co-morbid major depression and generalized
anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med 2008; 38:365.
7. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other
disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21:655.
8. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe--a critical review and
appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15:357.

https://www.uptodate.com/contents/496/print 15/20
3/29/23, 12:00 PM 496

9. Ruscio AM, Hallion LS, Lim CCW, et al. Cross-sectional Comparison of the Epidemiology of
DSM-5 Generalized Anxiety Disorder Across the Globe. JAMA Psychiatry 2017; 74:465.
10. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006; 368:2156.
11. Tyrer P, Seivewright H, Johnson T. The Nottingham Study of Neurotic Disorder: predictors of
12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med 2004;
34:1385.
12. Emmanuel J, Simmonds S, Tyrer P. Systematic review of the outcome of anxiety and
depressive disorders. Br J Psychiatry Suppl 1998; :35.
13. Brawman-Mintzer O, Lydiard RB, Emmanuel N, et al. Psychiatric comorbidity in patients
with generalized anxiety disorder. Am J Psychiatry 1993; 150:1216.

14. Beesdo K, Hoyer J, Jacobi F, et al. Association between generalized anxiety levels and pain in
a community sample: evidence for diagnostic specificity. J Anxiety Disord 2009; 23:684.
15. Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry 2009; 70
Suppl 2:20.
16. Gottschalk MG, Domschke K. Genetics of generalized anxiety disorder and related traits.
Dialogues Clin Neurosci 2017; 19:159.
17. Kendler KS. Major depression and generalised anxiety disorder. Same genes,
(partly)different environments--revisited. Br J Psychiatry Suppl 1996; :68.
18. Hettema JM, Prescott CA, Kendler KS. Genetic and environmental sources of covariation
between generalized anxiety disorder and neuroticism. Am J Psychiatry 2004; 161:1581.

19. Mackintosh MA, Gatz M, Wetherell JL, Pedersen NL. A twin study of lifetime Generalized
Anxiety Disorder (GAD) in older adults: genetic and environmental influences shared by
neuroticism and GAD. Twin Res Hum Genet 2006; 9:30.

20. Donner J, Sipilä T, Ripatti S, et al. Support for involvement of glutamate decarboxylase 1
and neuropeptide Y in anxiety susceptibility. Am J Med Genet B Neuropsychiatr Genet 2012;
159B:316.

21. Unschuld PG, Ising M, Specht M, et al. Polymorphisms in the GAD2 gene-region are
associated with susceptibility for unipolar depression and with a risk factor for anxiety
disorders. Am J Med Genet B Neuropsychiatr Genet 2009; 150B:1100.

22. You JS, Hu SY, Chen B, Zhang HG. Serotonin transporter and tryptophan hydroxylase gene
polymorphisms in Chinese patients with generalized anxiety disorder. Psychiatr Genet
2005; 15:7.

23. Sevy S, Papadimitriou GN, Surmont DW, et al. Noradrenergic function in generalized
anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry 1989;
https://www.uptodate.com/contents/496/print 16/20
3/29/23, 12:00 PM 496

25:141.

24. Garvey MJ, Noyes R Jr, Woodman C, Laukes C. The association of urinary 5-
hydroxyindoleacetic acid and vanillylmandelic acid in patients with generalized anxiety.
Neuropsychobiology 1995; 31:6.

25. Abelson JL, Glitz D, Cameron OG, et al. Blunted growth hormone response to clonidine in
patients with generalized anxiety disorder. Arch Gen Psychiatry 1991; 48:157.
26. Weizman R, Tanne Z, Granek M, et al. Peripheral benzodiazepine binding sites on platelet
membranes are increased during diazepam treatment of anxious patients. Eur J Pharmacol
1987; 138:289.
27. Ferrarese C, Appollonio I, Frigo M, et al. Decreased density of benzodiazepine receptors in
lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr
Scand 1990; 82:169.
28. Wemmie JA, Taugher RJ, Kreple CJ. Acid-sensing ion channels in pain and disease. Nat Rev
Neurosci 2013; 14:461.
29. Costello H, Gould RL, Abrol E, Howard R. Systematic review and meta-analysis of the
association between peripheral inflammatory cytokines and generalised anxiety disorder.
BMJ Open 2019; 9:e027925.
30. Moon CM, Jeong GW. Alterations in white matter volume and its correlation with clinical
characteristics in patients with generalized anxiety disorder. Neuroradiology 2015; 57:1127.
31. Wu JC, Buchsbaum MS, Hershey TG, et al. PET in generalized anxiety disorder. Biol
Psychiatry 1991; 29:1181.
32. Nitschke JB, Sarinopoulos I, Oathes DJ, et al. Anticipatory activation in the amygdala and
anterior cingulate in generalized anxiety disorder and prediction of treatment response.
Am J Psychiatry 2009; 166:302.
33. Goossen B, van der Starre J, van der Heiden C. A review of neuroimaging studies in
generalized anxiety disorder: "So where do we stand?". J Neural Transm (Vienna) 2019;
126:1203.
34. Hirsch CR, Meeten F, Krahé C, Reeder C. Resolving Ambiguity in Emotional Disorders: The
Nature and Role of Interpretation Biases. Annu Rev Clin Psychol 2016; 12:281.
35. Mathews A, Richards A, Eysenck M. Interpretation of homophones related to threat in
anxiety states. J Abnorm Psychol 1989; 98:31.
36. MacLeod C, Mathews A, Tata P. Attentional bias in emotional disorders. J Abnorm Psychol
1986; 95:15.

https://www.uptodate.com/contents/496/print 17/20
3/29/23, 12:00 PM 496

37. Goodwin H, Yiend J, Hirsch CR. Generalized Anxiety Disorder, worry and attention to threat:
A systematic review. Clin Psychol Rev 2017; 54:107.

38. Mogg K, Bradley BP, Millar N, White J. A follow-up study of cognitive bias in generalized
anxiety disorder. Behav Res Ther 1995; 33:927.
39. Mogg K, Baldwin DS, Brodrick P, Bradley BP. Effect of short-term SSRI treatment on
cognitive bias in generalised anxiety disorder. Psychopharmacology (Berl) 2004; 176:466.
40. Safren SA, Gershuny BS, Marzol P, et al. History of childhood abuse in panic disorder, social
phobia, and generalized anxiety disorder. J Nerv Ment Dis 2002; 190:453.

41. Bandoli G, Campbell-Sills L, Kessler RC, et al. Childhood adversity, adult stress, and the risk
of major depression or generalized anxiety disorder in US soldiers: a test of the stress
sensitization hypothesis. Psychol Med 2017; 47:2379.

42. Rosenbaum JF, Biederman J, Bolduc-Murphy EA, et al. Behavioral inhibition in childhood: a
risk factor for anxiety disorders. Harv Rev Psychiatry 1993; 1:2.
43. Tyrer P, Seivewright H, Johnson T. The core elements of neurosis: mixed anxiety-depression
(cothymia) and personality disorder. J Pers Disord 2003; 17:129.
44. Khan AA, Jacobson KC, Gardner CO, et al. Personality and comorbidity of common
psychiatric disorders. Br J Psychiatry 2005; 186:190.
45. Beck AT, Emery G, Greenberg RL. Anxiety Disorders and Phobias: A Cognitive Perspective, B
asic Books, New York 1985.
46. Barlow DH. Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic, Guilf
ord Press, New York 1988.

47. Borkovec TD, Alcaine O, Behar E. Avoidance theory of worry and generalized anxiety disord
er. In: Generalized Anxiety Disorder: Advances in Research and Parctice, Heimberg RG, Turk
CL, Mennin DS (Eds), Guilford Press, New York 2004. p.77.

48. Dugas MJ, Marchand A, Ladouceur R. Further validation of a cognitive-behavioral model of

generalized anxiety disorder: diagnostic and symptom specificity. J Anxiety Disord 2005;
19:329.

49. Roemer L, Molina S, Borkovec TD. An investigation of worry content among generally
anxious individuals. J Nerv Ment Dis 1997; 185:314.
50. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fif
th Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
51. Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in children and adolescents:
developmental issues and implications for DSM-V. Psychiatr Clin North Am 2009; 32:483.

https://www.uptodate.com/contents/496/print 18/20
3/29/23, 12:00 PM 496

52. Angst J, Gamma A, Baldwin DS, et al. The generalized anxiety spectrum: prevalence, onset,
course and outcome. Eur Arch Psychiatry Clin Neurosci 2009; 259:37.
53. Shores MM, Glubin T, Cowley DS, et al. The relationship between anxiety and depression: a
clinical comparison of generalized anxiety disorder, dysthymic disorder, panic disorder, and
major depressive disorder. Compr Psychiatry 1992; 33:237.
54. Rhebergen D, Aderka IM, van der Steenstraten IM, et al. Admixture analysis of age of onset
in generalized anxiety disorder. J Anxiety Disord 2017; 50:47.

55. Lenze EJ. Anxiety disorders in the elderly. In: Textbook of Anxiety Disorders, 2nd ed, Stein D
J, Hollander E, Rothbaum BO (Eds), American Psychiatric Publishing, Inc, Washington, DC 2
010. p.651.

56. Zhang X, Norton J, Carrière I, et al. Risk factors for late-onset generalized anxiety disorder:
results from a 12-year prospective cohort (the ESPRIT study). Transl Psychiatry 2015;
5:e536.

57. Chou KL. Age at onset of generalized anxiety disorder in older adults. Am J Geriatr
Psychiatry 2009; 17:455.
58. Zhang X, Norton J, Carrière I, et al. Generalized anxiety in community-dwelling elderly:
Prevalence and clinical characteristics. J Affect Disord 2015; 172:24.
59. Hoehn-Saric R, Hazlett RL, McLeod DR. Generalized anxiety disorder with early and late
onset of anxiety symptoms. Compr Psychiatry 1993; 34:291.
60. Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and
recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year
prospective study. Am J Psychiatry 2005; 162:1179.

61. Ramsawh HJ, Raffa SD, Edelen MO, et al. Anxiety in middle adulthood: effects of age and
time on the 14-year course of panic disorder, social phobia and generalized anxiety
disorder. Psychol Med 2009; 39:615.

62. Naragon-Gainey K, Gallagher MW, Brown TA. A longitudinal examination of psychosocial

impairment across the anxiety disorders. Psychol Med 2014; 44:1691.
63. Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid
generalized anxiety disorder and major depression at 12 months in two national surveys.
Am J Psychiatry 1999; 156:1915.
64. Wittchen HU, Carter RM, Pfister H, et al. Disabilities and quality of life in pure and comorbid
generalized anxiety disorder and major depression in a national survey. Int Clin
Psychopharmacol 2000; 15:319.

https://www.uptodate.com/contents/496/print 19/20
3/29/23, 12:00 PM 496

65. Tully PJ, Cosh SM, Baune BT. A review of the affects of worry and generalized anxiety
disorder upon cardiovascular health and coronary heart disease. Psychol Health Med 2013;
18:627.

66. Butnoriene J, Bunevicius A, Saudargiene A, et al. Metabolic syndrome, major depression,

generalized anxiety disorder, and ten-year all-cause and cardiovascular mortality in middle
aged and elderly patients. Int J Cardiol 2015; 190:360.

67. Gimson A, Schlosser M, Huntley JD, Marchant NL. Support for midlife anxiety diagnosis as
an independent risk factor for dementia: a systematic review. BMJ Open 2018; 8:e019399.
68. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and
Depression Scale. An updated literature review. J Psychosom Res 2002; 52:69.
69. Dear BF, Titov N, Sunderland M, et al. Psychometric comparison of the generalized anxiety
disorder scale-7 and the Penn State Worry Questionnaire for measuring response during
treatment of generalised anxiety disorder. Cogn Behav Ther 2011; 40:216.
Topic 496 Version 29.0

Contributor Disclosures
David Baldwin, MA, DM FRCPsych Consultant/Advisory Boards: Anxiety UK [Anxiety disorder]; Idorsia
[Sleep]; National Clinical Audit of Anxiety and Depression [Anxiety and depression]. All of the relevant
financial relationships listed have been mitigated. Murray B Stein, MD, MPH Equity Ownership/Stock
Options: EpiVario [Substance use disorders and PTSD]; Oxeia Biopharmaceuticals [Traumatic brain injury].
Consultant/Advisory Boards: Acadia Pharmaceuticals [Anxiety and traumatic stress-related disorders];
Aptinyx [Anxiety and traumatic stress-related disorders]; atai Life Sciences [Anxiety and traumatic stress-
related disorders]; Bionomics [Anxiety and traumatic stress-related disorders]; BioXcel Therapeutics
[Anxiety and traumatic stress-related disorders]; Boehringer-Ingelheim [Anxiety and traumatic stress-
related disorders]; Clexio [Anxiety and traumatic stress-related disorders]; Eisai [Anxiety and traumatic
stress-related disorders]; EmpowerPharm [Anxiety and traumatic stress-related disorders]; Engrail
Therapeutics [Anxiety and traumatic stress-related disorders]; GABA Therapeutics [Anxiety and traumatic
stress-related disorders]; Jazz Pharmaceuticals [Anxiety and traumatic stress-related disorders]; Oxeia
Biopharmaceuticals [Traumatic brain injury]; Roche/Genentech [Anxiety and traumatic stress-related
disorders]. Other Financial Interest: Biological Psychiatry [Deputy Editor]; Depression and Anxiety [Editor-
in-chief]. All of the relevant financial relationships listed have been mitigated. Michael Friedman, MD No
relevant financial relationship(s) with ineligible companies to disclose.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are
addressed by vetting through a multi-level review process, and through requirements for references to be
provided to support the content. Appropriately referenced content is required of all authors and must
conform to UpToDate standards of evidence.

Conflict of interest policy


https://www.uptodate.com/contents/496/print 20/20